In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%

Amgen is cutting the list price of its cholesterol drug Repatha by 60% to $5,850 in an unprecedented move to make the drug available to senior citizens.

“We’ve got to make sure those who need [Repatha] can get it,” says Robert Bradway, Amgen’s chairman and chief executive.